Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumor malignancy

Prostate

Volumn 32, Issue 1, 1997, Pages 9-15

  Lipponen, P ^a   Vesalainen, S ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Apoptosis; bcl 2; Flow cytometry; Grade; Morphometry; Progression; Prostatic adenocarcinoma; Survival

Indexed keywords

ESTROGEN DERIVATIVE; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; ESTROGEN THERAPY; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TRANSURETHRAL RESECTION;

ADENOCARCINOMA; APOPTOSIS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030972740     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970615)32:1<9::AID-PROS2>3.0.CO;2-I     Document Type: Article

References (36)

1. International Union Against Cancer (UICC): "TNM Classification of Malignant Tumours," 3rd ed. Geneva: UICC, 1978.
2. Olsen S: "Tumours of the Kidney and Urinary Tract." Mungsgaard, 1983.
3. Gleason DF: Histologic grading and clinical staging of prostatic carcinoma. In Tannenbaum M (ed.): "Urologic Pathology: The Prostate." Philadelphia: Lea & Febiger, 171, 1977.
4. Mostofi FK: Grading of prostatic carcinoma. Cancer Chemother Rep 59:111-117, 1975.
5. Visakorpi T, Kallioniemi O-P, Paronen IYI, Isola JJ, Heikkinen AI, Koivula TA: Flow cytometric analysis of DNA ploidy and S phase fraction from prostatic carcinomas: Implications for prognosis and response to endocrine therapy. Br J Cancer 64:578-582, 1991.
6. Song J, Cheng WS, Cupps RE, Earle JD, Farrow GM, Lieber MM: Nuclear deoxyribonucleic acid content measured by static cytometry: Important prognostic association for patients with clinically localized prostate carcinoma treated by external beam radiotherapy. J Urol 147:794-797, 1992.
7. Visakorpi T, Kallioniemi O-P, Heikkinen A, Koivula T, Isola J: Small subgroup of aggressive highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84: 883-887, 1992.
8. Harper ME, Goddard G-JL, Wilson DW, Matenhelia SS, Conn IG, Peeling WB, Griffiths K: Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. Prostate 20:243-253, 1992.
9. Vesalainen S, Lipponen P: Expression of retinoblastoma gene (Rb) protein in T12M0 prostatic adenocarcinoma. J Cancer Res Clin Oncol 121:429-433, 1995.
10. Wyllie AH: Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: An overview. Cancer Metast Rev 11:95-103, 1992.
11. Hockenbery DM: The bcl-2 oncogene and apoptosis. Semin Immunol 4:413-420, 1992.
12. Sachs L, Lotem J: Control of programmed cell death in normal and leukemic cells: New implications for therapy. Blood 82:15-21, 1993.
13. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G: The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch 424: 47-51, 1994.
14. Lipponen P, Pietiläinen T, Kosma V-M, Aaltomaa S, Eskelinen M, Syrjänen K: Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favorable prognosis. J Pathol 177:49-55, 1995.
15. Syrjänen KJ, Hjelt LH: Ultrastructural characteristics of human renal-cell carcinoma in relation to light microscopic grading. Scand J Urol Nephrol 12:57-65, 1978.
16. Black MM, Kerpe S, Speer FD: Survival in breast cancer cases in relation to the structure of the primary tumor and the regional lymph nodes. Surg Gynecol Obstet 100:543-548, 1955.
17. Walker NI, Harmon BV, Gobe GC, Kerr JFR: Patterns of cell death. Methods Achieve Exp Pathol 13:18-54, 1988.
18. Lipponen PK, Eskelinen MJ, Jauhiainen K, Harju E, Terho R: Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer 29A:69-75, 1993.
19. Aaltomaa S, Lipponen PK, Eskelinen MJ, Kosma V-M, Marin S, Alhava E, Syrjänen K: Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 28:859-864, 1992.
20. Lipponen PK, Nordling S, Eskelinen MJ, Jauhiainen K, Terho R, Harju E: Flow cytometry in comparison with mitotic index in predicting disease outcome in transitional-cell bladder cancer. Int J Cancer 53:42-47, 1993.
21. Haapasalo H, Pesonen E, Collan Y: Volume corrected mitotic index (M/V-index): The standard of mitotic activity in neoplasms. Pathol Res Pract 185:551-554, 1989.
22. Lee E, Desu M: A computer program for comparing k samples with right censored data. Comput Prog Biomed 2:315-320, 1972.
23. Cox DR: Regression models and life tables with discussion. J R Stat Soc B 34:187-220, 1972.
24. Lu QL, Poulsom R, Wong L, Hanby AM: BCL-2 expression in adult and embryonic non-hematopoietic tissues. J Pathol 169: 431-437, 1993.
25. Chleq-Deschamps CM, LeBrun DP, Huie P, Besnier DP, Warnke RA, Sibley RK, Cleary ML: Topographical dissociation of bcl-2 messenger RNA and protein expression in human lymphoid tissues. Blood 81:293-298, 1993.
26. LeBrun DP, Warnke RA, Cleary ML: Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol 142:743-753, 1993.
27. Hanada M, Krajewski S, Tanaka S, Carzals-Hatem D, Spengler BA, Ross RA, Biedler JL, Reed JC: Regulation of bcl-2 levels with differentiation of human neuroblastoma cells. Cancer Res 53: 4978-4986, 1993.
28. Nguyen M, Millar DG, Yong VW, Korsmeyer SJ, Shore GC: Targeting of bcl-2 to the mitochondrial outer membrane by a COOH-terminal. J Biol Chem 268:25265-25268, 1993.
29. de Jong D, Prins FA, Mason DY, Reed JC, van-Ommen GB, Kluin PM: Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res 54:256-260, 1991.
30. Schena M, Gottardi D, Chia P, Larsson LG, Carlsson M, Nilsson K, Caligaris-Cappio F: The role of bcl-2 in the pathogenesis of B chronic lymphocytic leukemia. Leuk Lymph 11:173-179, 1993.
31. Hollowood K, Macartney JC: Reduced apoptotic cell death in follicular lymphoma. J Pathol 163:337-342, 1991.
32. Lipponen P, Aaltomaa S: Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 173:333-340, 1994.
33. Colombel M, Symmans F, Gil S, Toole KMO, Chopin D, Benson M, Olsson CA, Korsmayer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143:390-400, 1993.
34. McDonnell TJ, Troncoso P, Brisbay SM, Logothesis C, Chung LWK, Hsieh J-T, Tu S-M, Campell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992.
35. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT: Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 2:389-398, 1996.
36. Huovinen R, Wärri A, Collan Y: Mitotic activity, apoptosis and TRPM-2 mRNA expression in DMBA-induced rat mammary carcinoma treated with anti-estrogen toremifene. Int J Cancer 55:685-691, 1993.